Regulation of Cytokines in Cancer PainView this Special Issue
Research Article | Open Access
Guiqin Zhu, Yanbin Dong, Xueming He, Ping Zhao, Aixing Yang, Rubing Zhou, Jianhua Ma, Zhong Xie, Xue-Jun Song, "Radiotherapy Suppresses Bone Cancer Pain through Inhibiting Activation of cAMP Signaling in Rat Dorsal Root Ganglion and Spinal Cord", Mediators of Inflammation, vol. 2016, Article ID 5093095, 8 pages, 2016. https://doi.org/10.1155/2016/5093095
Radiotherapy Suppresses Bone Cancer Pain through Inhibiting Activation of cAMP Signaling in Rat Dorsal Root Ganglion and Spinal Cord
Radiotherapy is one of the major clinical approaches for treatment of bone cancer pain. Activation of cAMP-PKA signaling pathway plays important roles in bone cancer pain. Here, we examined the effects of radiotherapy on bone cancer pain and accompanying abnormal activation of cAMP-PKA signaling. Female Sprague-Dawley rats were used and received tumor cell implantation (TCI) in rat tibia (TCI cancer pain model). Some of the rats that previously received TCI treatment were treated with X-ray radiation (radiotherapy). Thermal hyperalgesia and mechanical allodynia were measured and used for evaluating level of pain caused by TCI treatment. PKA mRNA expression in dorsal root ganglion (DRG) was detected by RT-PCR. Concentrations of cAMP, IL-1β, and TNF-α as well as PKA activity in DRG and the spinal cord were measured by ELISA. The results showed that radiotherapy significantly suppressed TCI-induced thermal hyperalgesia and mechanical allodynia. The level of PKA mRNA in DRG, cAMP concentration and PKA activity in DRG and in the spinal cord, and concentrations of IL-1β and TNF-α in the spinal cord were significantly reduced by radiotherapy. In addition, radiotherapy also reduced TCI-induced bone loss. These findings suggest that radiotherapy may suppress bone cancer pain through inhibition of activation of cAMP-PKA signaling pathway in DRG and the spinal cord.
Pain is one of the most prevalent symptoms in patients with primary bone sarcomas and with the distant metastases of nonbone primary tumors [1, 2]. Studies have indicated that bone cancer pain has complex and unique mechanisms that may involve both inflammatory and neuropathic pain . Clinically, most patients with bone cancer have already passed the optimal time for radical surgery and multidisciplinary therapies. However, with radiotherapy, majority of these patients experience pain relief, control of tumor growth, and prolonged survival. Radiotherapy is not only an effective method in the clinical treatment of bone cancer, but also an important approach for treatment of the severe pain associated with bone cancer. However, mechanisms underlying radiotherapy for bone cancer pain have not been well investigated and remain elusive.
Cyclic adenosine monophosphate-protein kinase A (cAMP-PKA) signaling pathway plays important roles in a number of cellular processes, including immune function , growth , differentiation , and metabolism , and is essential to the plasticity in neural synapses in CNS . Activation of cAMP-PKA pathway has been reported to enhance presynaptic neurotransmitter synthesis and vesicular transportation probably through phosphorylation of key transcriptional factors (i.e., cAMP response element-binding protein) and synaptic vesicle proteins [9–11]. In addition, recent studies found that cAMP-PKA signaling pathway is involved in both inflammatory pain [12–14] and neuropathic pain [15–17]. The peripheral hyperalgesic actions of inflammatory mediators are mediated by the cAMP-PKA signaling pathway . We have recently demonstrated that the cAMP-PKA pathway is crucial for the maintenance of dorsal root ganglia (DRG) neuronal hyperexcitability and behaviorally expressed hyperalgesia, in an in vivo neuropathic pain animal model of chronic compression of the DRG (CCD model), as well as in an in vitro model of acute DRG dissociation [15, 16, 18]. Recently, we have further found that activation of the cAMP-PKA signaling pathway plays an important role in both induction and maintenance of bone cancer pain in rats . However, it remains unknown whether and then how cAMP-PKA signaling would contribute toward radiotherapy treatment for bone cancer pain. This study provides evidence supporting an idea that radiotherapy may suppress bone cancer pain through inhibition of abnormal activation of cAMP-PKA signaling pathway in DRG and the spinal cord.
2. Materials and Methods
2.1. Animals and Drugs
Female adult Sprague-Dawley rats (160–180 g at the start of the experiment) were housed in a controlled lighting environment with free access to food and water. All experiments were approved by the Institutional Animal Care and Use Committees in Oriental Hospital and conducted in accordance with the Declaration of the National Institutes of Health Guide for the Care and Use of Laboratory Animals (publication number 85-23, revised 1985). Surgery was performed under anesthesia with intraperitoneal injection of sodium pentobarbital (50 mg/kg, i.p.).
2.2. Animal Model of Bone Cancer Pain
The protocols of the bone cancer pain model were similar to that described previously [19–21]. In brief, following induction of general anesthesia with intraperitoneal injection of sodium pentobarbital, rats were placed abdominal side up. After disinfecting with 75% v/v ethanol, a one-centimeter rostrocaudal incision was made in the skin directly above the top half of the tibia. Tumor cells (1 × 105 cells/μL, 5 μL), extracted from the ascetic fluid of female rats that received Walker 256 mammary gland carcinoma cells, were injected (tumor cell implantation, TCI) into the intramedullary space of the right tibia to induce bone cancer. Injection site was closed with bone wax while the syringe was removed. The incision was then dusted with penicillin powder and closed. Rats in the sham group were injected with the same number of boiled tumor cells.
A single dose of radiation was given 9 days after TCI. Rats were immobilized in an acryl jig, and a dose of 6 Gy was delivered to the right tibia area using a collimator system with 6 MV X-rays . Sham radiotherapy applied in TCI rats was using the same protocol, except that they were not given the real X-ray radiation.
2.4. Radiographic Observation
On the 17th day after TCI treatment, radiographic images were taken (exposure setting: 12 ms, 31 KVp) using a Philips Digital Radiographer System (Digital Diagnost VM; Philips Medical Systems DMC GmbH, Hamburg, Germany). Bone destruction was evaluated on a scale of 0–5 [20, 23]: 0 = normal bone structure without any sign of deterioration; 1 = small radiolucent lesions in the proximal epiphysis (<3); 2 = increased number of radiolucent lesions (>3) indicating loss of medullary bone; 3 = loss of medullary bone, plus erosion of the cortical bone; 4 = full-thickness unicortical bone loss; and 5 = full-thickness bicortical bone loss and displaced fracture. The experimenter was blinded to the treatment of the samples.
2.5. Behavioral Test
Thermal hyperalgesia was indicated by a significantly shortened latency of foot withdrawal in response to heat stimulation. To determine thermal hyperalgesia, a radiant heat source was focused and delivered on a portion of the hind paw; the thermal stimuli shut off automatically when hind paw moved (or after 20 s to prevent tissue damage). Thermal stimuli were delivered 3 times to each hind paw at 5–8-minute intervals. Mechanical allodynia was indicated by a significant decrease in the threshold of paw withdrawal to mechanical indentation of the plantar surface of each hind paw, with a sharp, cylindrical probe. The probe was applied to 6 designated loci distributed over the plantar surface of the foot. The minimal force that induced paw withdrawal was read off the display [19, 24]. The experimenters who performed these behavioral tests were blinded to the treatment condition of the animals.
2.6. mRNA Isolation and RT-PCR
The total RNA isolated with TRIzol Reagent (Invitrogen, USA) was reverse transcribed using M-MLV reverse transcriptase (Takara). Primer sets were synthesized by Integrated DNA Technologies (Sangon Biotech); their sequences are shown in Table 1. The amplification conditions were set as follows: 94°C for 2 min and 30 cycles of 94°C for 30 s and 58°C for 40 s. PCR products were analyzed on agarose gel electrophoresis and were verified by DNA sequencing. The gels were imaged with Tanon 2500 Imaging Systems and analyzed by analysis software ImageJ 1.48u.
2.7. Measurement of cAMP, IL-1β, and TNF-α Levels and PKA Activity
The DRG and the spinal cord at segments of L4-L5 ipsilateral to TCI were collected on postoperative days 10 and 14 for further neurochemical analysis. Commercial enzyme-linked immunosorbent assay kits were used to determine the concentrations of cAMP, IL-1β, and TNF-α and activity of PKA, according to the manufacturers’ instructions. ELISA kit for cAMP was purchased from Cayman Chemical (Ann Arbor, Michigan, USA); ELISA kits for IL-1β, TNF-α, and activated PKA were purchased from R&D Systems (Minneapolis, Minnesota, USA).
2.8. Statistical Analysis
All statistical analyses were carried out using Statistical Product and Service Solutions, ver. 15.0 (SPSS Inc., Chicago, Illinois, USA). Alterations in cAMP mRNA and concentration, PKA activity, and the levels of IL-1β and TNF-α were tested using one-way analysis of variance (ANOVA) followed by Bonferroni post hoc tests. Two-way repeated-measures ANOVA (days × groups) was used to test the behavioral responses to thermal and mechanical stimuli, followed by Bonferroni post hoc tests. The nonparametric statistical method was used for analyzing the bone radiographs. All data were presented as means ± SEM. Statistical results were deemed significant if value was less than 0.05.
3.1. Radiotherapy Attenuated TCI-Induced Thermal Hyperalgesia and Mechanical Allodynia
TCI-treated rats exhibited significant thermal hyperalgesia and mechanical allodynia during postoperative days 5–17. The thresholds of thermal and mechanical withdrawal ipsilateral, but not contralateral, to the TCI treatment decreased approximately by 50% during postoperative days 9–17 compared to sham control. To determine whether radiotherapy treatment affects bone cancer pain, a single dose of X-radiation (6 Gy) was applied on the 9th day after operation. Such radiotherapy produced long-lasting inhibition of TCI-induced thermal hyperalgesia and mechanical allodynia. The inhibition lasted for a week with 1 d delay following the X-radiation application. The peak values of inhibition of the thermal hyperalgesia and mechanical allodynia were approximately 25–50%. The thermal and mechanical withdrawal of the hind paw contralateral to TCI treatment was not altered following the radiotherapy. Data are summarized in Figure 1.
3.2. Radiotherapy Alleviated TCI-Induced Bone Destruction
Bone structure integrity was evaluated by radiographic observation on the 17th day after TCI. No radiographic change (score = 0, no bone destruction) was found in the group of sham without radiotherapy. Bone destruction was seen clearly in groups of TCI with and without radiotherapy, respectively. Score of the TCI group with sham therapy was (range: 3–5). Radiotherapy greatly reduced TCI-induced tibia bone destruction. The score in the group of TCI with radiotherapy dropped to (range: 1–3), which was significantly less than the score in TCI group with sham therapy. Radiological changes of the tibia are shown in Figure 2.
3.3. Radiotherapy Inhibited TCI-Induced PKA mRNA Expression in DRG
Our previous studies have shown that expression of PKA-RII and PKA-C mRNAs was increased after TCI treatment in a time-dependent manner . To test whether radiotherapy has an effect on this TCI-induced PKA mRNA expression, we measured the levels of PKA-RII and PKA-C mRNAs on day 1 and day 5 after radiotherapy treatment (postoperative days 10 and 14, resp.) using RT-PCR. We found that radiotherapy treatment greatly inhibited TCI-induced increase of expression of PKA-RII and PKA-C mRNA. The expression of PKA-RII and PKA-C mRNA in the TCI + radiotherapy group was significantly reduced compared with the TCI + sham group (Figure 3).
3.4. Radiotherapy Reduced TCI-Induced Increase of cAMP Level and PKA Activity in DRG and the Spinal Cord
We have previously shown that cAMP concentration and PKG activity in DRG and the spinal cord were significantly increased in a time-dependent manner after TCI treatment . To test the hypothesis that cAMP-PKA signaling pathway might be altered by radiotherapy, we measured cAMP level and PKA activity in DRG and the spinal cord following radiotherapy treatment. The results showed that radiotherapy treatment significantly reduced TCI-induced increase of cAMP concentration as well as PKA activity in DRG and the spinal cord (Figure 4).
3.5. Radiotherapy Reduced TCI-Induced Activity of IL-1β and TNF-α in the Spinal Cord
We have recently shown that IL-1β and TNF-α levels in the spinal cord were significantly increased in a time-dependent manner after TCI treatment . To test whether radiotherapy could affect TCI-induced increase of IL-1β and TNF-α, we measured levels of IL-1β and TNF-α in the spinal cord after radiotherapy on postoperative days 10 and 14 (1 and 5 days after radiotherapy). Our results showed that radiotherapy treatment significantly reduced TCI-induced increase of IL-1β and TNF-α in the spinal cord (Figure 5).
This study demonstrates that radiotherapy is an effective treatment approach for treating bone cancer pain. The cAMP-PKA signaling pathway may be a mechanism that underlies the analgesic effect of radiotherapy in bone cancer pain. Radiotherapy suppresses TCI-induced painful behaviors, thermal hyperalgesia, and mechanical allodynia and alleviates TCI-induced massive bone destruction. Radiotherapy reduces TCI-induced increased expression of PKA mRNAs in DRG as well as the increased level of cAMP concentration and PKA activity in both DRG and the spinal cord. In addition, radiotherapy results in a significant decrease of IL-1β and TNF-α activity in the spinal cord. These findings suggest that radiotherapy treatment may suppress TCI-induced hyperalgesia and allodynia by inhibiting the cAMP-PKA signaling pathway in DRG and the spinal cord.
Pain is one of the most prominent symptoms in clinically advanced cancer patients. Approximately 50% of these patients experience moderate to severe pain . Mechanisms of cancer pain are thought to be complex and may involve a combination of inflammation, nerve injury, and other unique factors . Considerable evidence of cancer pain treatment shows that radiotherapy effectively relieves pain in up to 95% of patients and can maintain the level of analgesia in more than 70% of the patients for up to three months [27–29]. Previous studies have shown that activation of the cAMP-PKA signaling pathway contributes to noxious stimulus-induced peripheral and central sensitization [30–32]. We have found that in vivo chronic compression of DRG or in vitro acute DRG dissociation resulted in activation of the cAMP-PKA signaling pathway. Continued activation of the cAMP-PKA signaling pathway is required to maintain hyperexcitability of the DRG neurons and behaviorally expressed hyperalgesia in these two different injury-related stress conditions [15, 17]. Recently, we have confirmed that activation of the cAMP-PKA pathway plays an essential role in the induction and maintenance of bone cancer pain [19, 25]. Here, we provide direct evidence that the elevated activity of cAMP-PKA signaling pathway is significantly decreased by radiotherapy in a bone cancer pain model. These results support an idea that radiotherapy may suppress bone cancer pain through inhibition of abnormal activation of cAMP-PKA signaling pathway, suggesting a new mechanism for the radiotherapy of bone cancer pain.
The proinflammatory cytokines are activators of the cAMP-PKA pathway in primary afferent neurons [25, 33–35]. During tumor growth and development of bone cancer pain, certain proinflammatory cytokines such as TNF-α and IL-1β are activated and released from the astrocytes and microglial cells and contribute to bone cancer pain [25, 36, 37]. Radiotherapy can reduce these proinflammatory cytokines and inhibit activation of the cAMP-PKA signaling pathway and thus result in relief of bone cancer pain. These findings suggest that the cytokines are also targets that may be responsible for radiotherapy-induced analgesia. In addition, our results showed that radiotherapy resulted in less bone loss in TCI rats. This is consistent with the previous finding that radiotherapy with high dose may kill part of the tumor cells or reduce their activation and thus delay the destruction of the bone structure [38, 39]. These findings indicate that radiotherapy may reduce both pain and loss of bone structure following TCI treatment.
Our results demonstrate that radiotherapy can effectively suppress bone cancer pain probably through inhibition of activation of cAMP-PKA signaling pathway in the primary sensory neurons and the spinal cord. This study may suggest a new mechanism underlying radiotherapy-induced analgesia of bone cancer pain and support the clinical use of radiotherapy in treatment of certain cancer pain conditions.
This study should be attributed equally to the institutions.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
Guiqin Zhu and Yanbin Dong contributed equally to this study.
This work was partly supported by grants from Jiangsu Province Distinguished Medical Expert (JPDME2014-123), Lianyungang City Project 555-2 (LYG-555-2) and the Municipal Science and Technology Bureau Foundation (SH1338, SH1420), and the National Nature Science Foundation of China (NSFC-81271241 and 81320108012).
- H. Breivik, N. Cherny, B. Collett et al., “Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes,” Annals of Oncology, vol. 20, no. 8, pp. 1420–1433, 2009.
- M. H. J. van den Beuken-van Everdingen, J. M. de Rijke, A. G. Kessels, H. C. Schouten, M. van Kleef, and J. Patijn, “Prevalence of pain in patients with cancer: a systematic review of the past 40 years,” Annals of Oncology, vol. 18, no. 9, pp. 1437–1449, 2007.
- M. J. Goblirsch, P. Zwolak, and D. R. Clohisy, “Advances in understanding bone cancer pain,” Journal of Cellular Biochemistry, vol. 96, no. 4, pp. 682–688, 2005.
- C. H. Serezani, M. N. Ballinger, D. M. Aronoff, and M. Peters-Golden, “Cyclic AMP: master regulator of innate immune cell function,” American Journal of Respiratory Cell and Molecular Biology, vol. 39, no. 2, pp. 127–132, 2008.
- P. J. S. Stork and J. M. Schmitt, “Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation,” Trends in Cell Biology, vol. 12, no. 6, pp. 258–266, 2002.
- K. Yamamizu and J. K. Yamashita, “Roles of cyclic adenosine monophosphate signaling in endothelial cell differentiation and arterial-venous specification during vascular development,” Circulation Journal, vol. 75, no. 2, pp. 253–260, 2011.
- G. G. Holz, E. Heart, and C. A. Leech, “Synchronizing Ca2+ and cAMP oscillations in pancreatic β-cells: a role for glucose metabolism and GLP-1 receptors? Focus on ‘Regulation of cAMP dynamics by Ca2+ and G protein-coupled receptors in the pancreatic β-cell: a computational approach’,” The American Journal of Physiology—Cell Physiology, vol. 294, no. 1, pp. C4–C6, 2008.
- R. Waltereit and M. Weller, “Signaling from cAMP/PKA to MAPK and synaptic plasticity,” Molecular Neurobiology, vol. 27, no. 1, pp. 99–106, 2003.
- W. Koppert, “Opioid-induced hyperalgesia. Pathophysiology and clinical relevance,” Anaesthesist, vol. 53, no. 5, pp. 455–466, 2004.
- T. King, M. H. Ossipov, T. W. Vanderah, F. Porreca, and J. Lai, “Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance?” Neurosignals, vol. 14, no. 4, pp. 194–205, 2004.
- S. Tumati, W. R. Roeske, T. M. Largent-Milnes, T. W. Vanderah, and E. V. Varga, “Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats,” Journal of Neuroscience Methods, vol. 199, no. 1, pp. 62–68, 2011.
- C. M. Hingtgen, K. J. Waite, and M. R. Vasko, “Prostaglandins facilitate peptide release from rat sensory neurons by activating the adenosine 3′, 5′-cyclic monophosphate transduction cascade,” The Journal of Neuroscience, vol. 15, no. 7, pp. 5411–5419, 1995.
- A. B. Malmberg, E. P. Brandon, R. L. Idzerda, H. Liu, G. S. McKnight, and A. I. Basbaum, “Diminished inflammation and nociceptive pain with preservation of neuropathic pain in mice with a targeted mutation of the type I regulatory subunit of cAMP-dependent protein kinase,” The Journal of Neuroscience, vol. 17, no. 19, pp. 7462–7470, 1997.
- M. R. Lewin and E. T. Walters, “Cyclic GMP pathway is critical for inducing long-term sensitization of nociceptive sensory neurons,” Nature Neuroscience, vol. 2, no. 1, pp. 18–23, 1999.
- X.-J. Song, Z.-B. Wang, Q. Gan, and E. T. Walters, “cAMP and cGMP contribute to sensory neuron hyperexcitability and hyperalgesia in rats with dorsal root ganglia compression,” Journal of Neurophysiology, vol. 95, no. 1, pp. 479–492, 2006.
- Z.-J. Huang, H.-C. Li, A. A. Cowan, S. Liu, Y.-K. Zhang, and X.-J. Song, “Chronic compression or acute dissociation of dorsal root ganglion induces cAMP-dependent neuronal hyperexcitability through activation of PAR2,” Pain, vol. 153, no. 7, pp. 1426–1437, 2012.
- J.-H. Zheng, E. T. Walters, and X.-J. Song, “Dissociation of dorsal root ganglion neurons induces hyperexcitability that is maintained by increased responsiveness to cAMP and cGMP,” Journal of Neurophysiology, vol. 97, no. 1, pp. 15–25, 2007.
- K. O. Aley and J. D. Levine, “Role of protein kinase A in the maintenance of inflammatory pain,” The Journal of Neuroscience, vol. 19, no. 6, pp. 2181–2186, 1999.
- G.-Q. Zhu, S. Liu, D.-D. He, Y.-P. Liu, and X.-J. Song, “Activation of the cAMP-PKA signaling pathway in rat dorsal root ganglion and spinal cord contributes toward induction and maintenance of bone cancer pain,” Behavioural Pharmacology, vol. 25, no. 4, pp. 267–276, 2014.
- S. J. Medhurst, K. Walker, M. Bowes et al., “A rat model of bone cancer pain,” Pain, vol. 96, no. 1-2, pp. 129–140, 2002.
- Q.-L. Mao-Ying, J. Zhao, Z.-Q. Dong et al., “A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells,” Biochemical and Biophysical Research Communications, vol. 345, no. 4, pp. 1292–1298, 2006.
- H. C. Park, J. Seong, J. H. An, J. Kim, U. J. Kim, and B. W. Lee, “Alteration of cancer pain-related signals by radiation: proteomic analysis in an animal model with cancer bone invasion,” International Journal of Radiation Oncology Biology Physics, vol. 61, no. 5, pp. 1523–1534, 2005.
- N. M. Luger, D. B. Mach, M. A. Sevcik, and P. W. Mantyh, “Bone cancer pain: from model to mechanism to therapy,” Journal of Pain and Symptom Management, vol. 29, no. 5, pp. S32–S46, 2005.
- X.-J. Song, J.-H. Zheng, J.-L. Cao, W.-T. Liu, X.-S. Song, and Z.-J. Huang, “EphrinB-EphB receptor signaling contributes to neuropathic pain by regulating neural excitability and spinal synaptic plasticity in rats,” Pain, vol. 139, no. 1, pp. 168–180, 2008.
- S. Liu, Y.-P. Liu, W. B. Song, and X.-J. Song, “EphrinB-EphB receptor signaling contributes to bone cancer pain via Toll-like receptor and proinflammatory cytokines in rat spinal cord,” Pain, vol. 154, no. 12, pp. 2823–2835, 2013.
- J. R. Ghilardi, H. Röhrich, T. H. Lindsay et al., “Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain,” The Journal of Neuroscience, vol. 25, no. 12, pp. 3126–3131, 2005.
- A. Lin and M. E. Ray, “Targeted and systemic radiotherapy in the treatment of bone metastasis,” Cancer and Metastasis Reviews, vol. 25, no. 4, pp. 669–675, 2006.
- D. Rades, S. E. Schild, and J. L. Abrahm, “Treatment of painful bone metastases,” Nature Reviews Clinical Oncology, vol. 7, no. 4, pp. 220–229, 2010.
- E. Chow, K. Harris, G. Fan, M. Tsao, and W. M. Sze, “Palliative radiotherapy trials for bone metastases: a systematic review,” Journal of Clinical Oncology, vol. 25, no. 11, pp. 1423–1436, 2007.
- Q.-P. Ma and C. J. Woolf, “Basal and touch-evoked fos-like immunoreactivity during experimental inflammation in the rat,” Pain, vol. 67, no. 2-3, pp. 307–316, 1996.
- C.-N. Liu, P. D. Wall, E. Ben-Dor, M. Michaelis, R. Amir, and M. Devor, “Tactile allodynia in the absence of C-fiber activation: altered firing properties of DRG neurons following spinal nerve injury,” Pain, vol. 85, no. 3, pp. 503–521, 2000.
- S.-J. Hu, X.-J. Song, K. W. Greenquist, J.-M. Zhang, and R. H. LaMotte, “Protein kinase A modulates spontaneous activity in chronically compressed dorsal root ganglion neurons in the rat,” Pain, vol. 94, no. 1, pp. 39–46, 2001.
- M. Cui and G. D. Nicol, “Cyclic AMP mediates the prostaglandin E2-induced potentiation of bradykinin excitation in rat sensory neurons,” Neuroscience, vol. 66, no. 2, pp. 459–466, 1995.
- S. Neumann, T. P. Doubell, T. Leslie, and C. J. Woolf, “Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons,” Nature, vol. 384, no. 6607, pp. 360–364, 1996.
- J. A. M. Smith, C. L. Davis, and G. M. Burgess, “Prostaglandin E2-induced sensitization of bradykinin-evoked responses in rat dorsal root ganglion neurons is mediated by cAMP-dependent protein kinase A,” European Journal of Neuroscience, vol. 12, no. 9, pp. 3250–3258, 2000.
- M. Yao, X.-Y. Chang, Y.-X. Chu et al., “Antiallodynic effects of propentofylline elicited by interrupting spinal glial function in a rat model of bone cancer pain,” Journal of Neuroscience Research, vol. 89, no. 11, pp. 1877–1886, 2011.
- R.-X. Zhang, B. Liu, L. Wang et al., “Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia,” Pain, vol. 118, no. 1-2, pp. 125–136, 2005.
- M. Goblirsch, C. Lynch, W. Mathews, J. C. Manivel, P. W. Mantyh, and D. R. Clohisy, “Radiation treatment decreases bone cancer pain through direct effect on tumor cells,” Radiation Research, vol. 164, no. 4, pp. 400–408, 2005.
- G. D. Roodman, “Mechanisms of bone metastasi,” The New England Journal of Medicine, vol. 350, no. 16, pp. 1655–1698, 2004.
Copyright © 2016 Guiqin Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.